AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 30th Annual Healthcare Conference

LEXINGTON, Mass., Mar 02, 2010 (BUSINESS WIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian
J.G. Pereira, MD, President and CEO, will present an overview of the
Company at the Cowen and Company 30th Annual Healthcare
Conference on March 9 at 3:45 p.m. ET. The Conference is being held
March 8-11, 2010 in Boston, MA.

A live webcast of the presentation will be accessible through the
Investors section of the Company’s website at
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until March 23, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

SOURCE: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals
Carol Miceli, 617- 498-3361